Recombinant Human IFNA17 protein (rFc Tag)(HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human IFNA17 protein (rFc Tag)(HPLC verified) (Eg3088)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3088

---

Validation Data Gallery

• 

  Purity of Recombinant Human IFNA17 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human IFNA17 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human IFNA17 protein Cys24-Asp189 (Accession# P01571) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 3451
• Accession: P01571
• PredictedSize: 45.3 kDa
• SDS-PAGE: 40-47 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Interferons (IFNs) are a family of cytokines with potent antiviral, antiproliferative, and immunomodulatory properties. There is no mouse homolog for IFNA17, but mature human IFNA17 shares 58% amino acid sequence identity with chimpanzee IFNA17. Type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha-subunit) and IFNAR2 (beta-subunit). Individual IFNA subtypes are known to display unique efficacies to viral protection. IFNA17 has been shown to be potent against HIV-1 activity. Human IFNA17 is the only IFNA subtype identified with antiviral activity but a reduced ability to activate NK cells. A mutation in IFNA17, Ile184Arg, is associated with an increased risk for cervical cancer.In summary, IFNA17 is a type I interferon with unique antiviral and immunomodulatory properties. It plays a significant role in the immune response and has been implicated in the pathogenesis of certain diseases, including prostate cancer and cervical cancer.

References:

1.	Pestka S, et al. (1987) Annu Rev Biochem. 56:727.
2.	Goeddel, D.V. et al. (1980) Nature 287:411.
3.	Ortaldo, J.R. et al. (1984) PNAS 81:4926.
4.	Kim, J.W. et al. (2003) Cancer Lett. 189:183.